Investing.com - Royalty Pharma (NASDAQ: RPRX) reported second quarter EPS of $0.96, $0.03 worse than the analyst estimate of $0.99. Revenue for the quarter came in at $608M versus the consensus estimate of $627.21M.
Royalty Pharma's stock price closed at $27.25. It is down -2.99% in the last 3 months and down -12.73% in the last 12 months.
Royalty Pharma saw 3 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Royalty Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Royalty Pharma's Financial Health score is "great performance".
Check out Royalty Pharma's recent earnings performance, and Royalty Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar.